1. Bækur og afþreying
  2. Bækur og kort
  3. Rafbækur

The Biology of Cancer, 2e

Rafræn bók. Uppl. sendar á netfangið þitt eftir kaup
Rafbók til eignar. Rafbók til eignar þarf að hlaða niður á þau tæki sem þú vilt nota innan eins árs frá því bókin er keypt. Útgáfa: 2
Fá vöru senda með tölvupósti


  • Copyright page
  • Dedication
  • Preface
  • A Note to the Reader
  • Acknowledgments
  • Contents
  • List of Key Techniques
  • Detailed Contents
  • Chapter 1 The Biology and Genetics of Cells and Organisms
    • 1.1 Mendel establishes the basic rules of genetics
    • 1.2 Mendelian genetics helps to explain Darwinian evolution
    • 1.3 Mendelian genetics governs how both genes and chromosomes behave
    • 1.4 Chromosomes are altered in most types of cancer cells
    • 1.5 Mutations causing cancer occur in both the germ line and the soma
    • 1.6 Genotype embodied in DNA sequences creates phenotype through proteins
    • 1.7 Gene expression patterns also control phenotype
    • 1.8 Histone modification and transcription factors control gene expression
    • 1.9 Heritable gene expression is controlled through additional mechanisms
    • 1.10 Unconventional RNA molecules also affect the expression of genes
    • 1.11 Metazoa are formed from components conserved over vast evolutionary time periods
    • 1.12 Gene cloning techniques revolutionized the study of normal and malignant cells
    • Additional reading
  • Chapter 2 The Nature of Cancer
    • 2.1 Tumors arise from normal tissues
    • 2.2 Tumors arise from many specialized cell types throughout the body
    • 2.3 Some types of tumors do not fit into the major classifications
    • 2.4 Cancers seem to develop progressively
    • 2.5 Tumors are monoclonal growths
    • 2.6 Cancer cells exhibit an altered energy metabolism
    • 2.7 Cancers occur with vastly different frequencies in different human populations
    • 2.8 The risks of cancers often seem to be increased by assignable influences including lifestyle
    • 2.9 Specific chemical agents can induce cancer
    • 2.10 Both physical and chemical carcinogens act as mutagens
    • 2.11 Mutagens may be responsible for some human cancers
    • 2.12 Synopsis and prospects
    • Key concepts
    • Thought questions
    • Additional reading
  • Chapter 3 Tumor Viruses
    • 3.1 Peyton Rous discovers a chicken sarcoma virus
    • 3.2 Rous sarcoma virus is discovered to transform infected cells in culture
    • 3.3 The continued presence of RSV is needed to maintain transformation
    • 3.4 Viruses containing DNA molecules are also able to induce cancer
    • 3.5 Tumor viruses induce multiple changes in cell phenotype including acquisition of tumorigenicity
    • 3.6 Tumor virus genomes persist in virus-transformed cells by becoming part of host-cell DNA
    • 3.7 Retroviral genomes become integrated into the chromosomes of infected cells
    • 3.8 A version of the src gene carried by RSV is also present in uninfected cells
    • 3.9 RSV exploits a kidnapped cellular gene to transform cells
    • 3.10 The vertebrate genome carries a large group of proto-oncogenes
    • 3.11 Slowly transforming retroviruses activate proto-oncogenes by inserting their genomes adjacent
    • 3.12 Some retroviruses naturally carry oncogenes
    • 3.13 Synopsis and prospects
    • Key concepts
    • Thought questions
    • Additional reading
  • Chapter 4 Cellular Oncogenes
    • 4.1 Can cancers be triggered by the activation of endogenous retroviruses?
    • 4.2 Transfection of DNA provides a strategy for detecting nonviral oncogenes
    • 4.3 Oncogenes discovered in human tumor cell lines are related to those carried by transforming retr
    • 4.4 Proto-oncogenes can be activated by genetic changes affecting either protein expression or struc
    • 4.5 Variations on a theme: the myc oncogene can arise via at least three additional distinct mechani
    • 4.6 A diverse array of structural changes in proteins can also lead to oncogene activation
    • 4.7 Synopsis and prospects
    • Key concepts
    • Thought questions
    • Additional reading
  • Chapter 5 Growth Factors, Receptors, and Cancer
    • 5.1 Normal metazoan cells control each other’s lives
    • 5.2 The Src protein functions as a tyrosine kinase
    • 5.3 The EGF receptor functions as a tyrosine kinase
    • 5.4 An altered growth factor receptor can function as an oncoprotein
    • 5.5 A growth factor gene can become an oncogene: the case of sis
    • 5.6 Transphosphorylation underlies the operations of receptor tyrosine kinases
    • 5.7 Yet other types of receptors enable mammalian cells to communicate with their environment
    • 5.8 Nuclear receptors sense the presence of low–molecular–weight lipophilic ligands
    • 5.9 Integrin receptors sense association between the cell and the extracellular matrix
    • 5.10 The Ras protein, an apparent component of the downstream signaling cascade, functions as a G pr
    • 5.11 Synopsis and prospects
    • Key concepts
    • Thought questions
    • Additional reading
  • Chapter 6 Cytoplasmic Signaling Circuitry Programs Many of the Traits of Cancer
    • 6.1 A signaling pathway reaches from the cell surface into the nucleus
    • 6.2 The Ras protein stands in the middle of a complex signaling cascade
    • 6.3 Tyrosine phosphorylation controls the location and thereby the actions of many cytoplasmic signa
    • 6.4 SH2 and SH3 groups explain how growth factor receptors activate Ras and acquire signaling specif
    • 6.5 Ras-regulated signaling pathways: A cascade of kinases forms one of three important signaling pa
    • 6.6 Ras-regulated signaling pathways: a second downstream pathway controls inositol lipids and the A
    • 6.7 Ras-regulated signaling pathways: a third downstream pathway acts through Ral, a distant cousin
    • 6.8 The Jak–STAT pathway allows signals to be transmitted from the plasma membrane directly to the
    • 6.9 Cell adhesion receptors emit signals that converge with those released by growth factor receptor
    • 6.10 The Wnt–ß-catenin pathway contributes to cell proliferation
    • 6.11 G-protein–coupled receptors can also drive normal and neoplastic proliferation
    • 6.12 Four additional “dual-address” signaling pathways contribute in various ways to normal and
    • 6.13 Well-designed signaling circuits require both negative and positive feedback controls
    • 6.14 Synopsis and prospects
    • Key concepts
    • Thought questions
    • Additional reading
  • Chapter 7 Tumor Suppressor Genes
    • 7.1 Cell fusion experiments indicate that the cancer phenotype is recessive
    • 7.2 The recessive nature of the cancer cell phenotype requires a genetic explanation
    • 7.3 The retinoblastoma tumor provides a solution to the genetic puzzle of tumor suppressor genes
    • 7.4 Incipient cancer cells invent ways to eliminate wild-type copies of tumor suppressor genes
    • 7.5 The Rb gene often undergoes loss of heterozygosity in tumors
    • 7.6 Loss-of-heterozygosity events can be used to find tumor suppressor genes
    • 7.7 Many familial cancers can be explained by inheritance of mutant tumor suppressor genes
    • 7.8 Promoter methylation represents an important mechanism for inactivating tumor suppressor genes
    • 7.9 Tumor suppressor genes and proteins function in diverse ways
    • 7.10 The NF1 protein acts as a negative regulator of Ras signaling
    • 7.11 Apc facilitates egress of cells from colonic crypts
    • 7.12 Von Hippel–Lindau disease: pVHL modulates the hypoxic response
    • 7.13 Synopsis and prospects
    • Key concepts
    • Thought questions
    • Additional reading
  • Chapter 8 pRb and Control of the Cell Cycle Clock
    • 8.1 Cell growth and division is coordinated by a complex array of regulators
    • 8.2 Cells make decisions about growth and quiescence during a specific period in the G1 phase
    • 8.3 Cyclins and cyclin-dependent kinases constitute the core components of the cell cycle clock
    • 8.4 Cyclin–CDK complexes are also regulated by CDK inhibitors
    • 8.5 Viral oncoproteins reveal how pRb blocks advance through the cell cycle
    • 8.6 pRb is deployed by the cell cycle clock to serve as a guardian of the restriction-point gate
    • 8.7 E2F transcription factors enable pRb to implement growth-versus-quiescence decisions
    • 8.8 A variety of mitogenic signaling pathways control the phosphorylation state of pRb
    • 8.9 The Myc protein governs decisions to proliferate or differentiate
    • 8.10 TGF-ß prevents phosphorylation of pRb and thereby blocks cell cycle progression
    • 8.11 pRb function and the controls of differentiation are closely linked
    • 8.12 Control of pRb function is perturbed in most if not all human cancers
    • 8.13 Synopsis and prospects
    • Key concepts
    • Thought questions
    • Additional reading
  • Chapter 9 p53 and Apoptosis: Master Guardian and Executioner
    • 9.1 Papovaviruses lead to the discovery of p53
    • 9.2 p53 is discovered to be a tumor suppressor gene
    • 9.3 Mutant versions of p53 interfere with normal p53 function
    • 9.4 p53 protein molecules usually have short lifetimes
    • 9.5 A variety of signals cause p53 induction
    • 9.6 DNA damage and deregulated growth signals cause p53 stabilization
    • 9.7 Mdm2 destroys its own creator
    • 9.8 ARF and p53-mediated apoptosis protect against cancer by monitoring intracellular signaling
    • 9.9 p53 functions as a transcription factor that halts cell cycle advance in response to DNA damage
    • 9.10 p53 often ushers in the apoptotic death program
    • 9.11 p53 inactivation provides advantage to incipient cancer cells at a number of steps in tumor pro
    • 9.12 Inherited mutant alleles affecting the p53 pathway predispose one to a variety of tumors
    • 9.13 Apoptosis is a complex program that often depends on mitochondria
    • 9.14 Both intrinsic and extrinsic apoptotic programs can lead to cell death
    • 9.15 Cancer cells invent numerous ways to inactivate some or all of the apoptotic machinery
    • 9.16 Necrosis and autophagy: two additional forks in the road of tumor progression
    • 9.17 Synopsis and prospects
    • Key concepts
    • Thought questions
    • Additional reading
  • Chapter 10 Eternal Life: Cell Immortalization and Tumorigenesis
    • 10.1 Normal cell populations register the number of cell generations separating them from their ance
    • 10.2 Cancer cells need to become immortal in order to form tumors
    • 10.3 Cell-physiologic stresses impose a limitation on replication
    • 10.4 The proliferation of cultured cells is also limited by the telomeres of their chromosomes
    • 10.5 Telomeres are complex molecular structures that are not easily replicated
    • 10.6 Incipient cancer cells can escape crisis by expressing telomerase
    • 10.7 Telomerase plays a key role in the proliferation of human cancer cells
    • 10.8 Some immortalized cells can maintain telomeres without telomerase
    • 10.9 Telomeres play different roles in the cells of laboratory mice and in human cells
    • 10.10 Telomerase-negative mice show both decreased and increased cancer susceptibility
    • 10.11 The mechanisms underlying cancer pathogenesis in telomerase-negative mice may also operate dur
    • 10.12 Synopsis and prospects
    • Key concepts
    • Thought questions
    • Additional reading
  • Chapter 11 Multi-Step Tumorigenesis
    • 11.1 Most human cancers develop over many decades of time
    • 11.2 Histopathology provides evidence of multi-step tumor formation
    • 11.3 Cells accumulate genetic and epigenetic alterations as tumor progression proceeds
    • 11.4 Multi-step tumor progression helps to explain familial polyposis and field cancerization
    • 11.5 Cancer development seems to follow the rules of Darwinian evolution
    • 11.6 Tumor stem cells further complicate the Darwinian model of clonal succession and tumor progress
    • 11.7 A linear path of clonal succession oversimplifies the reality of cancer: intra-tumor heterogene
    • 11.8 The Darwinian model of tumor development is difficult to validate experimentally
    • 11.9 Multiple lines of evidence reveal that normal cells are resistant to transformation by a single
    • 11.10 Transformation usually requires collaboration between two or more mutant genes
    • 11.11 Transgenic mice provide models of oncogene collaboration and multi-step cell transformation
    • 11.12 Human cells are constructed to be highly resistant to immortalization and transformation
    • 11.13 Nonmutagenic agents, including those favoring cell proliferation, make important contributions
    • 11.14 Toxic and mitogenic agents can act as human tumor promoters
    • 11.15 Chronic inflammation often serves to promote tumor progression in mice and humans
    • 11.16 Inflammation-dependent tumor promotion operates through defined signaling pathways
    • 11.17 Tumor promotion is likely to be a critical determinant of the rate of tumor progression in man
    • 11.18 Synopsis and prospects
    • Key concepts
    • Thought questions
    • Additional reading
  • Chapter 12 Maintenance of Genomic Integrity and the Development of Cancer
    • 12.1 Tissues are organized to minimize the progressive accumulation of mutations
    • 12.2 Stem cells may or may not be targets of the mutagenesis that leads to cancer
    • 12.3 Apoptosis, drug pumps, and DNA replication mechanisms offer tissues a way to minimize the accum
    • 12.4 Cell genomes are threatened by errors made during DNA replication
    • 12.5 Cell genomes are under constant attack from endogenous biochemical processes
    • 12.6 Cell genomes are under occasional attack from exogenous mutagens and their metabolites
    • 12.7 Cells deploy a variety of defenses to protect DNA molecules from attack by mutagens
    • 12.8 Repair enzymes fix DNA that has been altered by mutagens
    • 12.9 Inherited defects in nucleotide-excision repair, base-excision repair, and mismatch repair lead
    • 12.10 A variety of other DNA repair defects confer increased cancer susceptibility through poorly un
    • 12.11 The karyotype of cancer cells is often changed through alterations in chromosome structure
    • 12.12 The karyotype of cancer cells is often changed through alterations in chromosome number
    • 12.13 Synopsis and prospects
    • Key concepts
    • Thought questions
    • Additional reading
  • Chapter 13 Dialogue Replaces Monologue: Heterotypic Interactions and the Biology of Angiogenesis
    • 13.1 Normal and neoplastic epithelial tissues are formed from interdependent cell types
    • 13.2 The cells forming cancer cell lines develop without heterotypic interactions and deviate from t
    • 13.3 Tumors resemble wounded tissues that do not heal
    • 13.4 Experiments directly demonstrate that stromal cells are active contributors to tumorigenesis
    • 13.5 Macrophages and myeloid cells play important roles in activating the tumor-associated stroma
    • 13.6 Endothelial cells and the vessels that they form ensure tumors adequate access to the circulati
    • 13.7 Tripping the angiogenic switch is essential for tumor expansion
    • 13.8 The angiogenic switch initiates a highly complex process
    • 13.9 Angiogenesis is normally suppressed by physiologic inhibitors
    • 13.10 Anti-angiogenesis therapies can be employed to treat cancer
    • 13.11 Synopsis and prospects
    • Key concepts
    • Thought questions
    • Additional reading
  • Chapter 14 Moving Out: Invasion and Metastasis
    • 14.1 Travel of cancer cells from a primary tumor to a site of potential metastasis depends on a ser
    • 14.2 Colonization represents the most complex and challenging step of the invasion–metastasis casc
    • 14.3 The epithelial–mesenchymal transition and associated loss of E-cadherin expression enable car
    • 14.4 Epithelial–mesenchymal transitions are often induced by contextual signals
    • 14.5 Stromal cells contribute to the induction of invasiveness
    • 14.6 EMTs are programmed by transcription factors that orchestrate key steps of embryogenesis
    • 14.7 EMT-inducing transcription factors also enable entrance into the stem cell state
    • 14.8 EMT-inducing TFs help drive malignant progression
    • 14.9 Extracellular proteases play key roles in invasiveness
    • 14.10 Small Ras-like GTPases control cellular processes such as adhesion, cell shape, and cell motil
    • 14.11 Metastasizing cells can use lymphatic vessels to disperse from the primary tumor
    • 14.12 A variety of factors govern the organ sites in which disseminated cancer cells form metastases
    • 14.13 Metastasis to bone requires the subversion of osteoblasts and osteoclasts
    • 14.14 Metastasis suppressor genes contribute to regulating the metastatic phenotype
    • 14.15 Occult micrometastases threaten the long-term survival of cancer patients
    • 14.16 Synopsis and prospects
    • Key concepts
    • Thought questions
    • Additional reading
  • Chapter 15 Crowd Control: Tumor Immunology and Immunotherapy
    • 15.1 The immune system functions to destroy foreign invaders and abnormal cells in the body’s tiss
    • 15.2 The adaptive immune response leads to antibody production
    • 15.3 Another adaptive immune response leads to the formation of cytotoxic cells
    • 15.4 The innate immune response does not require prior sensitization
    • 15.5 The need to distinguish self from non-self results in immune tolerance
    • 15.6 Regulatory T cells are able to suppress major components of the adaptive immune response
    • 15.7 The immunosurveillance theory is born and then suffers major setbacks
    • 15.8 Use of genetically altered mice leads to a resurrection of the immunosurveillance theory
    • 15.9 The human immune system plays a critical role in warding off various types of human cancer
    • 15.10 Subtle differences between normal and neoplastic tissues may allow the immune system to distin
    • 15.11 Tumor transplantation antigens often provoke potent immune responses
    • 15.12 Tumor-associated transplantation antigens may also evoke anti-tumor immunity
    • 15.13 Cancer cells can evade immune detection by suppressing cell-surface display of tumor antigens
    • 15.14 Cancer cells protect themselves from destruction by NK cells and macrophages
    • 15.15 Tumor cells launch counterattacks on immunocytes
    • 15.16 Cancer cells become intrinsically resistant to various forms of killing used by the immune sys
    • 15.17 Cancer cells attract regulatory T cells to fend off attacks by other lymphocytes
    • 15.18 Passive immunization with monoclonal antibodies can be used to kill breast cancer cells
    • 15.19 Passive immunization with antibody can also be used to treat B-cell tumors
    • 15.20 Transfer of foreign immunocytes can lead to cures of certain hematopoietic malignancies
    • 15.21 Patients’ immune systems can be mobilized to attack their tumors
    • 15.22 Synopsis and prospects
    • Key concepts
    • Thought questions
    • Additional reading
  • Chapter 16 The Rational Treatment of Cancer
    • 16.1 The development and clinical use of effective therapies will depend on accurate diagnosis of di
    • 16.2 Surgery, radiotherapy, and chemotherapy are the major pillars on which current cancer therapies
    • 16.3 Differentiation, apoptosis, and cell cycle checkpoints can be exploited to kill cancer cells
    • 16.4 Functional considerations dictate that only a subset of the defective proteins in cancer cells
    • 16.5 The biochemistry of proteins also determines whether they are attractive targets for interventi
    • 16.6 Pharmaceutical chemists can generate and explore
    • 16.7 Drug candidates must be tested on cell models as an initial measurement of their utility in who
    • 16.8 Studies of a drug’s action in laboratory animals are an essential part of pre-clinical testin
    • 16.9 Promising candidate drugs are subjected to rigorous clinical tests in Phase I trials in humans
    • 16.10 Phase II and III trials provide credible indications of clinical efficacy
    • 16.11 Tumors often develop resistance to initially effective therapy
    • 16.12 Gleevec paved the way for the development of many other highly targeted compounds
    • 16.13 EGF receptor antagonists may be useful for treating a wide variety of tumor types
    • 16.14 Proteasome inhibitors yield unexpected therapeutic benefit
    • 16.15 A sheep teratogen may be useful as a highly potent anti-cancer drug
    • 16.16 mTOR, a master regulator of cell physiology, represents an attractive target for anti-cancer t
    • 16.17 B-Raf discoveries have led to inroads into the melanoma problem
    • 16.18 Synopsis and prospects: challenges and opportunities on the road ahead
    • Key concepts
    • Thought questions
    • Additional reading
  • Abbreviations
  • Glossary
  • Index


Bókahillan þín er þitt svæði og þar eru bækurnar þínar geymdar. Þú kemst í bókahilluna þína hvar og hvenær sem er í tölvu eða snjalltæki. Einfalt og þægilegt!

Þú kemst í bækurnar hvar sem er
Þú getur nálgast allar raf(skóla)bækurnar þínar á einu augabragði, hvar og hvenær sem er í bókahillunni þinni. Engin taska, enginn kyndill og ekkert vesen (hvað þá yfirvigt).

Auðvelt að fletta og leita
Þú getur flakkað milli síðna og kafla eins og þér hentar best og farið beint í ákveðna kafla úr efnisyfirlitinu. Í leitinni finnur þú orð, kafla eða síður í einum smelli.

Glósur og yfirstrikanir
Þú getur auðkennt textabrot með mismunandi litum og skrifað glósur að vild í rafbókina. Þú getur jafnvel séð glósur og yfirstrikanir hjá bekkjarsystkinum og kennara ef þeir leyfa það. Allt á einum stað.

Hvað viltu sjá? / Þú ræður hvernig síðan lítur út
Þú lagar síðuna að þínum þörfum. Stækkaðu eða minnkaðu myndir og texta með multi-level zoom til að sjá síðuna eins og þér hentar best í þínu námi.

Fleiri góðir kostir
- Þú getur prentað síður úr bókinni (innan þeirra marka sem útgefandinn setur)
- Möguleiki á tengingu við annað stafrænt og gagnvirkt efni, svo sem myndbönd eða spurningar úr efninu
- Auðvelt að afrita og líma efni/texta fyrir t.d. heimaverkefni eða ritgerðir
- Styður tækni sem hjálpar nemendum með sjón- eða heyrnarskerðingu
Vörumerki: Norton
Vörunúmer: 9781317963462
Taka af óskalista
Setja á óskalista


Engar umsagnir
Lesa fleiri umsagnir

The Biology of Cancer, 2e

Vörumerki: Norton
Vörunúmer: 9781317963462
Rafræn bók. Uppl. sendar á netfangið þitt eftir kaup
9.990 kr.
Fá vöru senda með tölvupósti
9.990 kr.